Detail

Study ID: F Hoffman LaRoche Genentech WO40181 Breast Cancer Study

Title:

A PHASE II, MULTICENTER, RANDOMIZED STUDY TO COMPARE THE EFFICACY OF VENETOCLAX PLUS FULVESTRANT VERSUS FULVESTRANT IN WOMEN WITH ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER WHO EXPERIENCED DISEASE RECURRENCE OR PROGRESSION DURING OR AFTER CDK4/6 INHIBITOR THERAPY

Description:
Title: WO40181 A Phase II, Multicenter, Randomized study to compare the efficacy of Venetoclax plus Fulvestrant versus Fulvestrant in women with estrogen receptor-positive, her2-negative locally advanced or metastatic breast cancer who experienced disease recurrence or progression during or after CDK4/6 inhibitor therapy Description: This study compares the effectiveness of venetoclax in combination with fulvestrant compared to fulvestrant alone for women with hormone positive, HER2-negative breast cancer that has progressed or recurred during or after treatment with CDK4/6i therapy. 4 Key Inclusion/Exclusion Criteria including Age Range, if applicable: 1. Female patients age 18 and older 2. Patients may not have received more than 2 prior lines of hormonal therapy in the locally advanced or metastatic setting 3. Have disease that is measurable on CT scans 4. No untreated or active brain or CNS metastases
Location:
Sioux Falls Region
Principal Investigator:
Miroslaw Mazurczak, MD
Disease:
Breast - Invasive
Stage:
Phase II
Status:
Active - Open to Accrual